- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03593096
Acute Exposure to High Altitude on Heart Rate and Ventilation During Exercise
Acute Exposure to Hypoxia in Precapillary Pulmonary Hypertension: Physiological and Clinical Effects at Rest and During Exercise
Study Overview
Status
Conditions
Detailed Description
Low altitude baseline measurements will be performed in Zurich (460m asl) including Echocardiography, Right heart catheterization, 6MWT, pulmonary function test, clinical assessment and blood gas Analysis.
Randomly assigned to the order of testing, the participants will be tested in Low Altitude (Zurich, 470m) and at High Altitude (2500m).
During the exposure to High Altitude (2500m) and Low Altitude (Zurich; 470m) of up to 5 hours, the participants' heart rate and Ventilation will be compared under exercise.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland, 8091
- Respiratory Clinic, University Hospital of Zurich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent
- PH diagnosed according to internation Guidelines: mPAP ≥ 25 mmHg along with a PAWP ≤15 mmHg during right heart catheterization at the time of Initial diagnosis
- PH class 1 (PAH) or 4 (CTEPH)
- Stable condition, on the same medication for > 4 weeks
- Patient live permanently at an altitude < 1000m asl.
Exclusion Criteria:
- Resting PaO2 ≤7.3 kPA corresponding to the requirement of long-term oxygen therapy > 16hour daily (nocturnal oxygen therapy alone is allowed)
- Severe daytime hypercapnia (pCO2 > 6.5 kPa)
- Susceptibility to high altitude related diseases (AMS, HAPE, etc.) based on previous experienced discomfort at altitudes.
- Exposure to an altitude >1500m for ≥3 nights during the last 4 weeks before the study participation
- Residence > 1000m above sea level
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with Walking disability
- Women who are pregnant or breast feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Order A
The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
|
Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
|
|
EXPERIMENTAL: Order B
The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
|
Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart rate under exercise
Time Frame: within 5 hours
|
Change in heart rate under exercise during the exposure to High Altitude (2500m above sea level) and Low Altitude (Zurich; 470m).
|
within 5 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ventilation under exercise
Time Frame: within 5 hours
|
Change in Ventilation under exercise during the exposure to High Altitude
|
within 5 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-00455_B9
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Guangdong Provincial People's HospitalRecruitingIdiopathic Pulmonary HypertensionChina
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Poitiers University HospitalNot yet recruitingChronic Thromboembolic Pulmonary Hypertension (CTEPH) | Pulmonary Arterial Hypertension (PAH)
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
BayerCompletedPrimary HypertensionChina
-
Regeneron PharmaceuticalsRecruitingPulmonary Arterial Hypertension (PAH)United States, United Kingdom, Latvia, South Korea
Clinical Trials on Assessment at Low Altitude (470m above sea level)
-
University of ZurichCompleted
-
University of ZurichCompletedPulmonary HypertensionSwitzerland
-
University of ZurichCompletedPulmonary HypertensionSwitzerland
-
University of ZurichCompleted
-
University of ZurichCompleted
-
University of ZurichCompleted
-
University of ZurichCompletedPulmonary HypertensionSwitzerland
-
University of ZurichCompletedPulmonary HypertensionSwitzerland
-
University of ZurichCompletedHigh Altitude Pulmonary HypertensionSwitzerland
-
University of OttawaHopital Montfort; Natural Sciences and Engineering Research Council, Canada; Institut...RecruitingHypoxia | Energy Intake | Appetite | AltitudeCanada